The present invention concerns the development of new pharmacologically active compounds for the treatment of osteoporosis and in general bone diseases characterized by progressive loss of bone mass, such as rheumatoid arthritis, hyperparathyroidism, and bone cancer metastases.
The invention describes a method for the diagnosis of neurodegenerative diseases based on the measurement, in a peripheral blood sample, of ?-synuclein heteromeric complexes with ?-amyloid or Tau protein.
The present invention concerns the synthesis of small molecules, obtained by a totally innovative process, characterized by a stimulatory effect on the secretion of GLP-1, a gastrointestinal hormone.
The invention consists of a method to activate cyclic AMP (cAMP)-mediated intracellular response in renal cells by triggering the beta-3 subtype adrenergic receptor (BAR3).
The new patented compounds are based on a potent reversible noncovalent mechanism of action, which is useful for treating MAGL-mediated diseases, such as neuroinflammation/degeneration, pain, multiple sclerosis/amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease.
The present invention relates to the development of novel isoindoline derivatives as activators of AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in cellular metabolism. The compounds, with original chemical structure, can be usefully employed for the prevention and treatment of metabolic disorders, such as type II diabetes and obesity, as well as immune-mediated inflammatory diseases and cancer.
The present invention relates to the development of novel benzofuran derivatives able to activate AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in the regulation of immune homeostasis
The present invention relates to novel benzo[d]isothiazolic-3(2H)-one-1,1-dioxide core compounds able to effectively and selectively inhibiting the IX and XII isoforms of the enzyme carbonic anhydrase (CA), which are predominantly expressed in hypoxic and metastatic tumors.
The object of the present invention is the design, synthesis, and pharmacological evaluation of novel diphenylmethane core molecules, capable of simultaneously promoting activation of the autophagy process and lipid catabolism, both in vitro and in vivo. Their dual activity may represent a novel approach for the treatment of neurodegenerative diseases, such as Alzheimer.
The present invention concerns the development of new derivatives with apoptosis-modulating action by inhibition of the MDM2/p53 complex.
